Vanda Pharmaceuticals: Sleep Wake Disorders trials

The registry lists 11 Sleep Wake Disorders studies with Vanda Pharmaceuticals as lead sponsor. 3 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 1Phase 3 7Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantRecruitingNCT06701396Phase 3
• Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesRecruitingNCT05361707Phase 3
• Patient Registry of Blind Subjects With Sleep-related ProblemsRecruitingNCT01195558
• Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)CompletedNCT02130999Phase 4Results posted
• Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake DisorderCompletedNCT01430754Phase 3Results posted
• Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake DisorderCompletedNCT01163032Phase 3Results posted
• Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult VolunteersCompletedNCT00490945Phase 2Results posted
• Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)CompletedNCT04652882Phase 3
• Study of the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsCompletedNCT02776215Phase 1
• Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light PerceptionCompletedNCT01429116Phase 3
• Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionActive, not recruitingNCT01218789Phase 3